Public notifications

FINPEDMED / NORDICPEDMED aim to increase public awareness about the pediatric drug / medical device development and pediatric clinical trials in Finland and in other Nordic Countries. This can be promoted by publishing some basic information of the Service Requests submitted to FINPEDMED / NORDICPEDMED. Service Requests are preliminary inquiries of possible new trials OR proposed expert consultations, both addressed for the clinical trial feasibility evaluation, or for the medical / scientific assessment.

Service Request´s public information is listed on a table below. You may open each request and look for the details by clicking the bar arrow beside the number. Service Request category C includes Consultations and category R includes Basic feasibility assessment for a new clinical trial.

  • C3561-76: XLH
  • C3561-75: Aicardi Goutières Syndrome
  • R3561-241: Arginase 1 deficiency
  • R3561-233: Batten CLN3 disease
  • C3561-71: Alpha-1 antitrypsin deficiency (AATD)
  • C3561-70: Epilepsy: focal and idiopathic epilepsy.
  • C3561-69: Wilson Disease
  • R3561-231: RSV
  • R3561-230: acute pouchitis
  • R3561-228: Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS)
  • R3561-227: Moderately to severely active Ulcerative colitis or Crohn’s disease
  • R3561-226: Herpes Zoster
  • R3561-225: Congenital Hyperinsulinism
  • R3561-224: Chronic and episodic migraine
  • R3561-223: Duchenne Muscular Dystrophy
  • R3561-222: Adolescents and children with anemia associated with chronic kidney disease.
  • R3561-221: eosinophilic esophagitis
  • R3561-220: Insomnia Disorder
  • R3561-218: Type 1 Diabetes
  • R3561-217: moderate-to-severe atomic dermatitis (AD)
  • R3561-216: Asthma
  • R3561-215: ADHD
  • R3561-214: Kindney transplant recipient
  • R3561-213: heart failure due to left ventricular systolic dysfunction
  • R3561-212: migraine
  • R3561-209: Crohn’s Disease (CD) and Ulcerative Colitis (UC)
  • C3561-67: metakromaattinen leukodystrofia (MLD)
  • R3561-208: pediatric patients with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas receiving selumetinib
  • C3561-66: Alfa-mannosidosis and LHON
  • C3561-65: Renal complement-mediated diseases
  • R3561-207: NLRC4 Gain of Function
  • R3561-206: Insomnia disease
  • C3561-64: Nephropatic cystinosis
  • C3561-63: Insomnia disorder
  • C3561-62: Bardet Biedl Syndrome; Alström Syndrome
  • R3561-205: SMA type 2 and type 3a (treatment naive)
  • C3561-61: Metachromatic leukodystrophy (MLD)
  • R3561-204: hypereosinophilic syndrome
  • R3561-203: Neurofibromatosis Type 1 and Plexiform Neurofibromas
  • R3561-202: Hemophilia
  • R3561-201: Pruritis in adolescents on haemodialysis
  • C3561-60: NASH
  • R3561-200: Migraine
  • R3561-198: Peanut allergy
  • C3561-59: cyanotic congenital heart disease (CHD)
  • C3561-58: Obesity
  • R3561-197: neonatal critical care
  • C3561-57: Chronic kidney disease
  • R3561-196: Asthma
  • R3561-195: MS-disease
  • R3561-194: Juvenile PsA
  • R3561-193: Atopic Dermatitis
  • R3561-192: Familial hypercholesterolemia
  • C3561-55: Pediatric ALL
  • R3561-188: pulmonary arterial hypertension
  • R3561-187: Duschenne Muscular Dystrophy (DMD)
  • R3561-186: Spinal Muscular Atrophy
  • R3561-185: Spinal Muscular Atrophy
  • R3561-184: ILD
  • R3561-183: DMD patients with deletion amenable to Exon 51skipping
  • R3561-181: Episodic and/or Chronic Migraine
  • R3561-180: Mucopolysaccharidoses (MPS), type IV
  • R3561-176: Hypoparathyroidism
  • R3561-175: Influenza
  • C3561-54: Psoriasis
  • R3561-174: Epilepsy
  • R3561-173: CML and other leukemias, lymphoma, solid tumors
  • R3561-172: Duchenne Muscular Dystrophy
  • R3561-171: Retinopathy of prematurity
  • R3561-170: Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus
  • R3561-168: New onset T1DM
  • C3561-53: schizophrenia
  • R3561-165: Venous thromboembolic event
  • C3561-52: AGU
  • C3561-51: AGU patients
  • R3561-162: Heterozygous Familial Hypercholesterolemia
  • R3561-160: SMA (Spinal Muscular Atrophy) TYPE 2 and TYPE 3
  • C3561-50: Type 1 spinal muscular atrophy
  • R3561-159: Homozygous familial hypersholesterolemia
  • R3561-157: Type 2 diabetes
  • C3561-49: heterozygous familial hypercholesterolemia (children and adolescents)
  • C3561-48: severe ulcerative colitis (US) or Crohn’s disease (CD).
  • C3561-47: Cystic Fibrosis
  • R3561-156: Pediatric Atopic Dermatitis
  • R3561-155: Type II Diabetes
  • R3561-154: Respiratory Syncytial Virus
  • R3561-153: Psoriatic and enthesitis-related arthritis JIA subtypes
  • C3561-46: Cystic Fibrosis
  • R3561-152: Pulmonary Arterial Hypertension (PAH)
  • R3561-151: Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • R3561-150: Glucocorticoid induced Osteoporisis
  • R3561-149: recurrent pediatric clostridium difficile infections
  • R3561-148: Type 2 diabetes mellitus 10 -17 years old
  • R3561-147: venous thromboembolism
  • C3561-45: prohlylaxis of thrombotic complications in children born with a single ventricle
  • C3561-44: Crohn´s disease
  • R3561-146: Major Depressive Disorder (MDD)
  • C3561-43: Juvenile idiopathic arthritis
  • R3561-143: secondary thrombocytopenia
  • C3561-42: MDD (major depression disorder)
  • R3561-142: Persistent asthma on ICS/LABA treatment
  • R3561-141: Diebetes Mellitus type 1
  • R3561-140: Intravascular Procedures For Congenital Heart Disease
  • C3561-41: Children with persistent asthma
  • C3561-40: Paediatric Melanoma / Lymphoma
  • R3561-139: Repeated seizures
  • C3561-39: Single-dose study of oral rivaroxaban dry powder suspension formulation in children treated for thrombosis
  • R3561-138: Pediatric Treatment of VTE with rivaroxaban
  • R3561-137: Pediatric Treatment of VTE with rivaroxaban
  • C3561-37: Type 1 Diabetes Mellitus
  • R3561-136: MDD
  • R3561-133: Atopic Dermatitis
  • R3561-132: Heterozygous Familiar Hypercholesterolemia
  • R3561-131: neutropenia or expected neutropenia
  • R3561-130: Prevention of Chemotherapy-Induced Nausea and Vomiting
  • C3561-36:
  • C3561-35:
  • C3561-34:
  • R3561-129: euvolemic or hypervolemic hyponatremia
  • R3561-127: B-precursor ALL
  • R3561-126: pediatric type 2 diabetes
  • C3561-33:
  • R3561-125: Epilepsy
  • R3561-113: Opioid induced constipation